Pharma IQ Members

Market Access, Trends and Outlook

View All Posts
Regina Au
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells Read more
Tags:
October 25, 2016 by Regina Au

Clinical Trial Diary

View All Posts
Georger
George Clinical’s parent organisation, The George Institute for Global Health and its TEXTCARE application, has been named a top 10 finalist in this year’s Google Impact Challenge. With a top prize of AUD $750,000, The George Institute has the opportunity to use its proven text messaging platform to tackle chronic disease on a global scale.
Tags:
October 21, 2016 by George Clinical Representative

The Clinical Trial Diary

View All Posts
Georger
The scientific leadership model for conducting clinical trials is relatively new. Despite its novelty, scientific leadership continues to prove its worth when comparing recruitment metrics both before and after the addition of scientific leadership into some of the world’s most complex, multi-regional trials. The implementation of scientific Read more
Tags:
October 4, 2016 by George Clinical Representative
Georger
Extensive investigator networks, cultivated over the course of some of the world’s largest clinical trials into the risk factors for dementia, present an exciting opportunity for the future of dementia trials. Diabetes, hypertension, stroke, vascular disease, smoking, poor diet, physical inactivity and even depression have been linked to an Read more
Tags: investigator network, clinical, clinical trials, clinical trial supply. george clinical, dementia, dementia trials, George Institute for Global Health, Dr Candice Delcourt, Professor Bruce Neal, Professor Craig Anderson
August 2, 2016 by George Clinical Representative
Georger
A key step in developing a new drug is the transition from the laboratory to the human subject in a Phase I clinical trial, where the new compound is given to humans for the first time. A Phase I trial is the gateway between scientific research and clinical medicine. Generally, in-human Phase I studies are conducted in healthy male patients or Read more
Tags:
February 25, 2016 by George Clinical Representative

Women in Shared Services

View All Posts
Georger
The rising presence of clinical trials (CT) in the Asia-Pacific region is predominantly driven by the East Asian region which includes China, Japan, Korea, Taiwan and Hong Kong. Over the past decade, Korea has become a global clinical trial hub and is one of the leading clinical trial destinations in the Asian region; with approximately 80% of its Read more
Tags: clinical, south korea, korea, clinical trial, clinical sites, multinational clinical study, local clinical study, Korea National Enterprise for Clinical Trials | KoNECT | CRO | contract research organisation, R&A
March 22, 2016 by George Clinical Representative

View From The Consultants Chair

View All Posts
Robert Musterer
Whether you call it a clinical data repository (CDR) or a clinical data warehouse (CDW); it seems everyone (oh, all right - at least a lot of companies) are either building, or planning to build one.  Most of these companies have grand notions of bringing together data from a wide variety of sources to be able to glean new insights.  However the Read more
Tags: clinical data repositories | clinical data | Robert Musterer | Clinical Data Repository | clinical data wsarehouse
February 19, 2015 by Robert Musterer

Pharma Industry Excerpts

View All Posts
Tye Spillum
Within the last few years the Pharmaceutical industry has taken a change in direction. Outsourcing (CDMO - external manufacturing model) has become a normal course of business.
Tags: pharma outsourcing | CDMO
September 19, 2012 by Tye Spillum